Increased Plasma 11-Deoxycorticosterone During Spironolactone Medication

Publisher Website
Google Scholar
Abstract
The increase of plasma deoxycorticosterone (DOC) levels after administration of spironolactone is a real effect and not due to cross-interference of the drug or its metabolites with the DOC-assay. This is proved by in vitro and in vivo results. Of all the metabolites only canrenone interferes to some extent with DOC after liquid-liquid-extraction and paper chromatography. The antiserum is so highly specific that the final cross-interference of the total procedure amounts to less than 2% of the DOC plasma levels. In patients with Addison''s disease only a very small increase of DOC plasma levels can be observed after administration of spironolactone in contrast to normal subjects.

This publication has 1 reference indexed in Scilit: